Company Overview and News

5
Project ‘Fuchsia’: Google Is Quietly Working on a Successor to Android - Bloomberg

2018-07-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GOOGL OCLCF AAPL GOOG ORCL

2
SAP Raises 2018 Outlook as Cloud Sales Growth Outpaces Bookings - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SAP SAPGF OCLCF ORCL CALD

1
Firmer US dollar boosts corporate interest in currency hedging

2018-07-19 channelnewsasia
U.S. multinational companies are starting to reevaluate their currency hedging strategies after a surge in the dollar in recent months, as the impact of the stronger greenback starts to show up in second-quarter corporate earnings.
CUKPF OCLCF CCL TRI NFLX CCL CUK ORCL AKAM

1
Oracle (ORCL) Up 5.7% Since Earnings Report: Can It Continue?

2018-07-19 zacks
A month has gone by since the last earnings report for Oracle Corporation (ORCL - Free Report) . Shares have added about 5.7% in that time frame.
OCLCF ORCL

1
Firmer U.S. dollar boosts corporate interest in currency hedging

2018-07-19 reuters
NEW YORK (Reuters) - U.S. multinational companies are starting to reevaluate their currency hedging strategies after a surge in the dollar in recent months, as the impact of the stronger greenback starts to show up in second-quarter corporate earnings.
CUKPF OCLCF CCL NFLX CCL CUK ORCL AKAM

26
This 1 chart puts mega tech’s trillions of market value into eye-popping perspective - MarketWatch

2018-07-19 marketwatch
A picture is worth a thousand words but a pie chart may be more eloquent, especially when it comes to sizing up the giants of the tech industry.
FB GOOG GOOGL GM.WS.A GM.WS.B OCLCF AAPL GM.WS.C CSCO MSFT GM INTC GM.WSB ORCL

6
CenturyLink to Widen Cloud Offerings With Oracle FastConnect

2018-07-17 zacks
CenturyLink, Inc. (CTL - Free Report) recently announced that it will offer private access to Oracle Cloud with Oracle Cloud Infrastructure FastConnect to provide customers with a network experience that matches their cloud experience. Oracle Cloud is a cloud computing service offered by Oracle Corporation (ORCL - Free Report) . The communications provider’s Cloud Connect Solutions and Oracle's FastConnect service will allow customers to enjoy consistent performance and reliability of a direct and secure connection.
CMTL MU OCLCF CTL ORCL

2
In the Case of Oracle Stock, Boring Does Not Equal Bad

2018-07-12 investorplace
The solid fourth-quarter results from Oracle Corporation (NYSE:ORCL) put an end to the downside momentum. Even though the company also issued a first-quarter guidance of revenue growing just 1 to 3 percent in the current (first) quarter, favorable valuations and the prospects of the Cloud Services unit will continue drawing investors with a long-term time horizon.
OCLCF MSFT CRM ORCL

40
Should You Buy CRM Stock? 3 Pros, 3 Cons

2018-07-12 investorplace
No matter how you slice it, data is what makes the world go round these days. From the Internet of Things to artificial intelligence and machine learning, everyone is looking for ways to pull, process, store and share data. For that reason, it’s important to beef up your portfolio with a few big data stocks to ensure that you can capitalize on this trend, and there’s no purer data play than salesforce.
AMZN GOOGL OCLCF MSFT GOOG CRM ORCL

3
Tech Companies Jockey as Pentagon Says Cloud Contract Coming - Bloomberg

2018-07-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IBM OCLCF MSFT ORCL

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH

6
Kavanaugh Made a Mark on Drones and Net Neutrality. What's Next? - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB GOOGL OCLCF GOOG ORCL

15
Amazon as a Value Stock? Believe It - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IBM NOBGF UPS BC94 WBA SMSN NFLX CVS N21 OCLCF NOBGY ORCL SMSD

1
Stock Buybacks Are Booming, but Share Prices Aren’t Budging - WSJ

2018-07-09 wsj
U.S. companies are buying back record amounts of stock this year, but their shares aren’t getting the boost they bargained for.
OCLCF ORCL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...